-
Annual Review | Dr. Qian Jiang: Advances in CML Research in 2024
In 2024, the field of chronic myeloid leukemia (CML) witnessed significant breakthroughs in research and clinical advancements. From the development of novel therapeutic agents to the optimization of treatment strategies, from studies on treatment discontinuation to deeper explorations into disease mechanisms, these findings have expanded treatment options and brought new hope to patients. As we…
-
Annual Review | Dr. Huilai Zhang: Advances in Follicular Lymphoma in 2024
In recent years, the field of hematologic malignancies has witnessed remarkable breakthroughs, with Chinese researchers making increasingly significant contributions, particularly in cellular therapy. Their work has played a crucial role in advancing both scientific progress and clinical practice. As we step into the new year, Hematology Frontier has invited Dr. Huilai Zhang from Tianjin Medical…
-
ASH 2024丨Dr. Sumit Gupta: Standard Chemotherapy Combined with BiTE Prolongs Event-Free Survival in Standard-Risk B-ALL Pediatric Patients
From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA. Hematology experts and scholars from around the world gathered to discuss and exchange insights on the latest research advancements in the field.
-
ESMO China Voice | Dr. Guodong He: PDNet Model Enables Precise Selection of Patients for Immunotherapy, Significantly Improving Treatment Outcomes
________________________________________ Oncology Frontier: Immunotherapy has advanced rapidly in recent years, making the selection of patients who will benefit from treatment a key clinical challenge. Your ESMO-selected study explored the use…
-
CheckMate 9DW Breakthrough: Nivolumab and Ipilimumab Show Promise as First-Line Therapy for Unresectable Liver Cancer
Study Design and Key Characteristics The study enrolled 668 patients with unresectable HCC who had not previously received systemic therapy. Eligibility criteria required at least one measurable lesion, a Child-Pugh…
-
Paclitaxel Oral Solution Shines in Phase 3 Trial for Advanced Gastric Cancer Second-Line Treatment
Methods The study was conducted across 53 medical centers in China and included patients with unresectable, recurrent, or metastatic gastric cancer who had experienced disease progression after fluoropyrimidine- or fluoropyrimidine…
-
Pravastatin and Liver Fibrosis: Insights from the PROSPER Trial
A recent post-hoc analysis of the PROSPER trial, published in JHEP Reports (2025), highlights the impact of pravastatin in reducing all-cause mortality in elderly patients at risk of liver fibrosis.The…
-
Exploring the Future of Clinical Research in Hodgkin Lymphoma
In this insightful session, Dr. Wei Xu from Jiangsu Provincial People’s Hospital (The First Affiliated Hospital of Nanjing Medical University) shares her expertise on the foundations and clinical advancements in Hodgkin lymphoma (HL) research. This talk delves into key aspects of HL treatment strategies, research breakthroughs, and what the future holds for clinical applications. Don’t…
Connecting Medical Expertise through Media